关于用于仿真抗原受体细胞疗法的定量模型分析的DMPK观点:进展和挑战
Akihiko Goto1, Yuu Moriya1, Miyu Nakayama1
1Center of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
本综述详细介绍了CAR细胞治疗的药物代谢和药理动力学 (DMPK),强调了定量建模. 解决DMPK挑战对于推进CAR细胞疗法和改善患者治疗结果至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 化学抗原受体 (CAR) 细胞代表了癌症免疫疗法的重大进步,特别是在血液性恶性瘤中.
- 对于固体瘤,正在探索CAR细胞治疗,因此需要更深入地了解其药理动力学和代谢特征.
研究的目的:
- 为CAR细胞治疗提供药物代谢和药理动力学 (DMPK) 现状和挑战的全面审查.
- 突出定量建模和模拟 (M&S) 在应对这些 DMPK 挑战中的作用.
- 概述CAR细胞疗法翻译的未来前景和改进领域.
主要方法:
- 关于CAR细胞治疗和DMPK的当前文献的综述.
- 强调定量建模和模拟 (M&S) 方法.
- 分析定量模型分析的最新进展,包括临床数据表征和基于机制的建模.
主要成果:
- 汽车细胞疗法在血液癌症中取得了革命性的成功,并正在针对固体瘤进行研究.
- 定量建模和模拟是描述CAR细胞疗法的DMPK的重要工具.
- 进步包括通过基于机制的建模连接体外和体内数据.
结论:
- 通过一个强大的框架来解决DMPK的挑战,对于成功的CAR细胞疗法转换至关重要.
- 需要改善配方质量,动物模型,体外模型和生物分析方法.
- 增强DMPK的理解将促进高效的CAR细胞疗法,改善患者的生活.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
08:09Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
Published on: March 14, 2025
相关概念视频
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
